Immix Biopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Immix Biopharma (IMMX).

Price Target Range — 9 Quarters

Analyst Consensus — 7 Analysts

1S.Buy

6Buy

Consensus RatingBuy# Analysts7Avg. Consensus PT$24Upside to Avg. PT+185.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 29, 2026	Needham	Gil Blum	PT Raise	Buy	$21→$30
Sep 15, 2026	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$15→$26
Aug 11, 2026	Morgan Stanley	Judah Frommer	PT Cut	Overweight	$20→$19
Aug 10, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$20→$25
Jul 22, 2026	Needham	Gil Blum	Initiate	Buy	$21
Jun 18, 2026	B of A Securities	Tazeen Ahmad	Initiate	Buy	$27
Jun 17, 2026	LifeSci Capital	—	Initiate	Outperform	$19
May 22, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$15→$20
Mar 30, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$15
Mar 30, 2026	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$14→$15
Mar 27, 2026	Citizens	Reni J. Benjamin	Maintained	Market Outperform	$23
Mar 27, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$12→$15
Mar 25, 2026	Morgan Stanley	Judah Frommer	Initiate	Overweight	$20
Mar 9, 2026	Citizens	Reni Benjamin	Initiate	Market Outperform	$23
Feb 9, 2026	Mizuho	Graig Suvannavejh	Initiate	Outperform	$14
Dec 9, 2025	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$8→$12
Sep 12, 2025	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$7→$8
Jun 4, 2025	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$7
Feb 10, 2025	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$7
Jan 6, 2025	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$7

Analyst Ratings News

PRO
Needham Maintains Buy on Immix Biopharma, Raises Price Target to $30

Needham analyst Gil Blum maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $21 to $30.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Immix Biopharma, Raises Price Target to $26

Mizuho analyst Graig Suvannavejh maintains Immix Biopharma (NASDAQ:IMMX) with a Outperform and raises the price target from $15 to $26.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Immix Biopharma, Lowers Price Target to $19

Morgan Stanley analyst Judah Frommer maintains Immix Biopharma (NASDAQ:IMMX) with a Overweight and lowers the price target from $20 to $19.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $25

HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $20 to $25.

Benzinga Newsdesk

PRO
Needham Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $21

Needham analyst Gil Blum initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a Buy rating and announces Price Target of $21.

Benzinga Newsdesk

Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions

BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyloidosis and peak sales near $963 million.

Vandana Singh

Immix Biopharma Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Immix Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Needham Maintains Buy on Immix Biopharma, Raises Price Target to $30

PRO
Mizuho Maintains Outperform on Immix Biopharma, Raises Price Target to $26

PRO
Morgan Stanley Maintains Overweight on Immix Biopharma, Lowers Price Target to $19

PRO
HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $25

PRO
Needham Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $21

Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions

People Also Watch

People Also Watch

Immix Biopharma Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Immix Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRONeedham Maintains Buy on Immix Biopharma, Raises Price Target to $30

PROMizuho Maintains Outperform on Immix Biopharma, Raises Price Target to $26

PROMorgan Stanley Maintains Overweight on Immix Biopharma, Lowers Price Target to $19

PROHC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $25

PRONeedham Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $21

Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions

People Also Watch

People Also Watch

PRO
Needham Maintains Buy on Immix Biopharma, Raises Price Target to $30

PRO
Mizuho Maintains Outperform on Immix Biopharma, Raises Price Target to $26

PRO
Morgan Stanley Maintains Overweight on Immix Biopharma, Lowers Price Target to $19

PRO
HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $25

PRO
Needham Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $21